blood and marrow transplantation
DESCRIPTION
Blood and Marrow Transplantation. Francisco F. Lopez, MD Hematology and Medical Oncology Bone Marrow Transplantation. 1 st BMT Reunion (January 2004). Outline. History Definition Rationale Procedure Indications Our data Summary. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/1.jpg)
Blood and Marrow Transplantation
Francisco F. Lopez, MD
Hematology and Medical Oncology
Bone Marrow Transplantation
![Page 2: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/2.jpg)
1st BMT Reunion (January 2004)
![Page 3: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/3.jpg)
Outline
• History
• Definition
• Rationale
• Procedure
• Indications
• Our data
• Summary
![Page 4: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/4.jpg)
History of Blood and Marrow Transplantation in the Philippines
1990 1st marrow transplant at the NKTI
2001 1st peripheral blood stem cell transplant at NKTI
2002 St Luke’s Medical Center (SLMC)
2002 Asian Hospital Medical Center (AHMC)
2005 1st autologous stem cell transplant at AHMC
2005 1st cord blood transplant at SLMC
![Page 5: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/5.jpg)
The transfusion of the immature progenitor stem cells derived from a donor to the recipient (allogeneic); OR stem cells previously harvested from the patient (autologous).
It is NOT an operation / surgical procedure.
![Page 6: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/6.jpg)
“Let’s crack your bones wide open!”
![Page 7: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/7.jpg)
Stem cells
• Young immature cells that make up 0.5% to 5% of the marrow cells.
• Express CD34+
• Progenitor cells: self-renew and divide to become red and white cells, and platelets.
![Page 8: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/8.jpg)
![Page 9: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/9.jpg)
Stem cellsBone marrow2 to 5 x 108 TNC/kg weight of recipient with the maximum volume dictated by
the weight of the donor (20ml BM aspirate/kg)can be stored at room temperature for up to 24hrs until infusion into the
recipient or cryopreserved
Peripheral blood2.0 to 5.0 x 106 CD34+ cells/kg for auto/allo transplantscan be stored at 4 C overnight or cryopreserved with dimethyl sulfoxide
(DSMO)
Umbilical cord3.7 x 106 TNC/kg recipient body weightcan be stored at 4 C or 25 C for up to three days or cryopreserved with DSMO
![Page 10: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/10.jpg)
Rationale
![Page 11: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/11.jpg)
Two kinds
• Allogeneic: Donor– Matched or partially mismatched sibling– Unrelated – Cord blood
• Autologous: No donor– Stem cells are harvested from patient
![Page 12: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/12.jpg)
Allogeneic transplant
• involves the transfer of stem cells from donor to recipient to permanently replace all hematopoietic cells
• eradicate malignant cells with high dose chemotherapy +/- radiotherapy
• sufficient immunosuppression of the host to allow growth of the allograft
• immune mediated graft vs leukemia/lymphoma or graft vs tumor effect
![Page 13: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/13.jpg)
Human Leukocyte Antigen (HLA) typing
![Page 14: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/14.jpg)
Autologous transplant
• Increasing the dose of some chemotherapeutic agents may result in large increase in tumor cell kill
• Transfusing previously harvested stem cells of the patient will guarantee bone marrow recovery
![Page 15: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/15.jpg)
![Page 16: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/16.jpg)
ProcedureAllogeneic transplant
![Page 17: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/17.jpg)
![Page 18: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/18.jpg)
![Page 19: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/19.jpg)
![Page 20: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/20.jpg)
Schema -8 admit to hospital -7 Total body Irradiation -6 Total body Irradiation -5 Total body Irradiation -4 Total body Irradiation; Donor starts GCSF -3 Cytoxan (60mg/kg) -2 Cytoxan (60mg/kg) -1 Rest day and start cyclosporine IV 0 Harvest and infusion of stem cells +1 Methotrexate 15mg/mm +3 Methotrexate 10mg/mm +6 Methotrexate 10mg/mm +11 Methotrexate 10mg/mm
![Page 21: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/21.jpg)
![Page 22: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/22.jpg)
![Page 23: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/23.jpg)
WBC from day of transplant to recovery
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
-11 -9 -7 -5 -3 -1 0 1 3 5 7 9 11 13 15 17
WBC
![Page 24: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/24.jpg)
ProcedureAutologous transplant
![Page 25: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/25.jpg)
Procedure: The Harvest
D –10 Cyclophosphamide 1.5gm/mm D – 7 Start GCSF 10mcg/kgD – 6 D – 5D – 4D – 3D – 2D – 1 D 0 Harvest using apheresis machine (collect 2.5
x 106 / kgBW CD 34+ cells)
![Page 26: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/26.jpg)
![Page 27: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/27.jpg)
![Page 28: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/28.jpg)
The transplant
• Day -8 admit• Day -7 Total body irradiation• Day -6 Total Body irradiation• Day -5 Total body irradiation• Day -4 etoposide 60mg/kg IV• Day -3 rest• Day -2 cytoxan 100mg/kg IV• Day -1 rest• Day 0 infusion of stem cells• Day +5 begin GSCF 5mg/kg/day• Day +10 marrow recovery or engraftment
![Page 29: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/29.jpg)
Transfusion of stem cells
![Page 30: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/30.jpg)
Indications and Timing of Transplant
![Page 31: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/31.jpg)
Allogeneic TransplantMalignant
• Acute and chronic leukemias– AML, ALL, CML
• Myelodysplastic syndrome (MDS)
• Lymphomas (failed chemotherapy)
• Multiple myeloma
• Myeloproliferative diseases
![Page 32: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/32.jpg)
Allogeneic TransplantNon malignant
• Aplastic anemia
• Thalassemia
• Immune disorders
• Paroxysmal nocturnal hemoglobinuria (PNH)
![Page 33: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/33.jpg)
Autologous Transplant
• Multiple Myeloma
• Non-Hodgkins Lymphoma
• Hodgkins Disease
• Solid Tumors
• Autoimmune diseases (multiple sclerosis)
![Page 34: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/34.jpg)
Allogeneic BMT in Pediatric AML
Indications: All except
Down’s syndrome
t(8;21)
t(15;17)
inv 16
0
10
20
30
40
50
60
70
80
chemo
1st CR
> 1st CR
![Page 35: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/35.jpg)
Allogneic BMT in Pediatric ALLIndications:
t(9;22) t(4,11)3rd CR or higherrelapse on therapy or
w/in 12 months of end of therapy
May be offered:> 28 days to achieve CR2nd CR, relapse > 12 months of end of therapy
0
10
20
30
40
50
60
70
80
90chemogoodrisk
1st CRhigh risk
chemohigh risk
2nd CR
> 2nd CR
chemo
![Page 36: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/36.jpg)
Severe Aplastic Anemia
0
10
20
30
40
50
60
70
80
OS >40y/o <40y/o
IST
BMT
![Page 37: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/37.jpg)
Allogneic BMT in adult ALL
Poor risk features• WBC > 25,000• T(9;22) t(8;14) t(4;11)• Age > 30y/o• Extramedullary
disease• Requiring more than
4 weeks to achieve a CR 0
10
20
30
40
50
60
chemo
1st CR
> 1st CR
![Page 38: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/38.jpg)
Allogeneic BMT in adult AML
Prognostic indicators that predict outcome of standard chemotherapy based on cytogenetic abnormalities.
favorable: t(8;21) t(15;17) inv 16
Intermediate: del y; normal karyotype; 11q23
Poor: all others0
10
20
30
40
50
60
70chemo
1st CR
1strelapse/2nd CR
inductfail/ >2ndrelapse
![Page 39: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/39.jpg)
2nd BMT Reunion (January 2005)
![Page 40: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/40.jpg)
Complications During BMT
![Page 41: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/41.jpg)
• Nausea and Vomiting• Nutrition• Mouth Sores• Diarrhea• Infection• Renal complications• Veno-Occlusive disease of the liver (VOD)• Pancytopenia• Graft Rejection• Acute Graft vs Host Disease• Rash• Pulmonary complications• Death
![Page 42: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/42.jpg)
• Nausea and Vomiting– More common during the early part of
transplant– Round the clock anti emetic medications– During the recovery phase, nausea /
vomiting / abdominal pain (cramps) / diarrhea, the patient may have graft vs host disease (GVHD).
![Page 43: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/43.jpg)
• Nutrition– Low bacteria diet: no fresh fruit and
vegetables; served hot; no left over; tray should be clean;
– Appetite diminishes after chemotherapy– Total parenteral nutrition until patient can eat.
![Page 44: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/44.jpg)
• Mouth Sores– Mouth wash (nystatin and biotene)– Morphine pushes or drip when severe (face
will be swollen)– Thrush
![Page 45: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/45.jpg)
• Diarrhea– Chemotherapy induced (Cuclophosphamide)– Infection: Clostridium Defficile– GVHD (graft vs host disease)– Food induced (avoid creamy, milk, oily food)
![Page 46: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/46.jpg)
• Bacterial Infections– Gram negative – Gram positive (central line or skin); patient should
shower or sponge bath daily.– Antibiotics: third generation cephalosporin and
vancomycin
• Fungal– Pulmonary (aspergillus)– Yeast– Amphoteric B prophylaxis
• Viral– Herpes zoster– Acyclovir IV
![Page 47: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/47.jpg)
Prevention
• Isolation room : positive pressure
• Strict hand washing
• Mask
• No need for gown or gloves unless patient is positive for clostridum defficile
![Page 48: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/48.jpg)
• Renal Complications– Renal insufficiency– Drugs: cyclosporine, vancomycin,
amphotericin B)– Monitor I & 0 accurately every 12 hours.
Balance fluid I & 0. lasix IV given prn.
![Page 49: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/49.jpg)
• Liver Complications– Veno-Occlusive disease of the liver (VOD)
• Water retention• Tender liver• Elevated bilirubin
• Elevation in bilirubin and SGPT and SGOT– Medications: cyclosporine, TPN– GVHD
![Page 50: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/50.jpg)
• Pancytopenia– Blood and platelet transfusion– Platelet apheresis is always used– Blood and platelets should always be
available, filtered and irradiated.
![Page 51: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/51.jpg)
• Graft rejection– Engraftment occurs between two to three
weeks after transfusion of stem cells– Recipient develops antibodies against the
HLA antigen of the donor.– Incidence increases in heavily transfused
patients.– Prior transfusions without filter and random
donor platelets used
![Page 52: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/52.jpg)
• Graft versus host disease– Occurs when donor stem cells recognizes the
body of the recipient as foreign and attacks the body.
– Acute GVHD occurs during engraftment: diarrhea, elevated bilirubin and rash
– GVHD prophylaxis: cyclosporine IV, methotrexate IV
![Page 53: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/53.jpg)
• Rash– Drug– GVHD– infection
![Page 54: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/54.jpg)
• Pulmonary complications– Pneumonia– Pulmonary congestion
• Total fluid per day 3L to 4L
– Engraftment syndrome
![Page 55: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/55.jpg)
• Mortality– Infection– GVHD– Relapse
![Page 56: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/56.jpg)
3rd BMT Reunion (January 2006)
![Page 57: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/57.jpg)
Bone MarrowTransplant Data
![Page 58: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/58.jpg)
BMT Data: 27 patients since December 2002
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
2002 2003 2004 2005 2006 2007
allogeneic
![Page 59: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/59.jpg)
BMT Data• December 2002 to April 2007• 27 stem cell transplants
– 22 allogeneic – 5 autologous
• Ages: 8 months to 66 years old• Sex: 17M and 10F• Transplant Regimen:
– Chemotherapy only: 21– Fractionated total body irradiation + chemo: 6
• GVHD prophylaxis:– CSA + Methotrexate 17– CSA + Cellcept 5
![Page 60: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/60.jpg)
BMT Data: Donor
• Sex– Same sex: 10– Opposite sex: 12
• HLA match– Full sibling: 21– Mismatch: 1(HLA 4/6 from father)
![Page 61: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/61.jpg)
BMT Data• 22 allogeneic
– Acute myelogenous Leukemia 10• 1st CR 7• 2nd CR 1• Induction failure 2
– Acute lymphoblastic leukemia 4• 1st CR 1• > 1st CR 3
– Myelodysplastic syndrome 4– Chronic myelogenous leukemia 1– Severe aplastic anemia 1– Thalassemia 1– Metastatic (lung & bones) renal cell cancer 1
![Page 62: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/62.jpg)
BMT Data
• 5 Autologous – 3 multiple myeloma– 1 relapsed hodgkin’s disease– 1 acute myelogenous leukemia in 2nd CR
![Page 63: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/63.jpg)
ResultsAllogeneic• Harvested stem cells: mean 7 x 106 CD34+
cells / kg BW of patient• Range: 2.9 to 23.6 x 106 CD34+ cells • Days of harvest: mean 2 days• Range 1 to 4 daysAutologous• Harvested stem cells: mean 5.1 x 106 CD34+
cells / kg BW of patient• Range: 3.2 to 8.1 x 106 CD34+ cells • Days of harvest: mean 2 days• Range 1 to 4 days
![Page 64: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/64.jpg)
Results
• Engraftment (allo and auto)– Mean 13 days– Range: 10 to 18 days
![Page 65: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/65.jpg)
Morbidity
![Page 66: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/66.jpg)
Rejection
Acute: Patient with AML 1st CR did not engraft at all. Positive antibodies against HLA. Was salvaged with a second transplant using same donor.
Currently doing well and off immuno drugs
Delayed: Patient with thalassemia. Graft rejection after 1 year. Autologous recovery of marrow. Transfusion dependent.
![Page 67: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/67.jpg)
Acute Graft Vs Host Disease (AGVHD) in BMT
• Manifestation of alloreactivity and occurs when mature T cells are transferred to hosts expressing histocompatibility differences
• Donor CD4+ and CD8+ target major tissues of the skin, liver and intestinal tract
![Page 68: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/68.jpg)
![Page 69: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/69.jpg)
Acute Graft vs Host Disease (GVHD) n = 15/22
Grade # of pts1 52 73 24 1
![Page 70: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/70.jpg)
Causes of GVHD
Causes
• HLA disparity
• Conditioning regimen
• Sex mismatch
• Age
• Parous donor
• Peripheral blood vs marrow
![Page 71: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/71.jpg)
Infection
• 8 had either gram (+) or gram (-) bacterial infection
• 1 had recurrence of PTB during transplant. He was an auto transplant patient with relapsed hodgkin’s disease, (+) history of treated PTB
• 4 had herpes zoster, months after
• 1 had anal warts, months after
![Page 72: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/72.jpg)
Cytomegalovirus (CMV)
• 9/14 developed (+) CMV blood culture within 100 days of transplant.
• They were successfully treated with ganciclovir for six weeks.
• Risks of developing CMV:– HLA mismatch– AGVHD– (+) serum CMV antibody
![Page 73: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/73.jpg)
Mortality n = 11• Infection (Gm negative septic shock) 2
– 10 and 11 days post transplant
– history of prior infections– poor performance status
• Severe AGVHD of the GIT 1• Relapse disease 8
– 2 ALL > 1st CR– 3 myelodysplastic syndrome– 1 AML induction failure– 1 AML auto – 1 multiple myeloma auto
![Page 74: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/74.jpg)
survival
• Allogeneic: 13/22
• Autologous: 3/5
• 16/27 survivors
• 1st patient transplanted is now 4yrs and 5 months post transplant
• Data may change in time – wait for 2 to 3 years
![Page 75: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/75.jpg)
Survival
0
10
20
30
40
50
60
70
80
90
100
OS
DFS
![Page 76: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/76.jpg)
Improve outcome
• Education and information– Can be done in our country– Dispel myths
• Not a surgical procedure• Harvesting stem cells is not a painful procedure• Maximum hospital stay 6 weeks• Live a normal life
• Screen candidates
• Early transplant and not later on (not a last resort)
![Page 77: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/77.jpg)
Burst my bubble!
![Page 78: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/78.jpg)
Kicking leukemia away!
![Page 79: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/79.jpg)
Survival
![Page 80: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/80.jpg)
Cost
![Page 81: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/81.jpg)
Cost
Factors– Age– Disease and status of disease– Weight– Complications– Regimen used
![Page 82: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/82.jpg)
Cost
• Range (Php 0.8M to Php 3M)– Adult (Php 1.7M)– Pediatric (Php 1.4M)
• Beyond what most Filipinos can afford
• The cost of BMT abroad is more expensive– Israel US$ 100,000– USA $250,000 to $500,000
![Page 83: Blood and Marrow Transplantation](https://reader036.vdocuments.us/reader036/viewer/2022081417/56814860550346895db56d60/html5/thumbnails/83.jpg)
4rd BMT Reunion (February 2007)